

Retro-CAG-eGFP-RG (Catalog#TBS7202)**DESCRIPTION**

Retro-CAG-eGFP-RG was packaged in HEK293T cells with $\text{Ca}_3(\text{PO}_4)_2$ transfection of 3 plasmids of pRetro-CAG-GFP, pRetro-RC, and pCMV-RG. The pRetro-CAG-GFP was constructed by using the components of Moloney Murine Leukemia virus (MoMLV), a combination of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter (CAG), and enhanced green fluorescent protein (eGFP) expression cassette. The pCMV-RG is expressed the envelop protein of rabies virus. Retro-CAG-eGFP-RG is a replication deficient virus and has potentials to infect many types of cell and tissue. It belongs to biosafety level-1 (BSL-1).

Retro-CAG-eGFP-RG is provided as concentrated viral supernatant at a titer around 10^6 IU/ml in HEK293T cells.

KEY FEATURES

Bright GFP expression: The Retro-CAG-eGFP-RG can express the green fluorescent protein brightly in many cultured cells and animals.

Replication deficient virus: The Retro-CAG-eGFP-RG is replication deficient virus.

APPLICATIONS

Neuroscience: The Retro-CAG-eGFP-RG can be used in nervous system.

Virology: The Retro-CAG-eGFP-RG can be used as a control virus in virological researches.

Gene therapy research: The Retro-CAG-eGFP-RG can be used as a control retroviral vector when the targeted gene expressed by using retroviral vector in neurological field.

CONTENTS

Retro-CAG-eGFP-RG: 20ul/vial in PBS.

Storage conditions. The product is shipped on dry ice. Store at -80°C .

METHOD OF DISPOSAL

Spill: Contain spill and decontaminate the area using a disinfectant such as chlorine bleach (10% final concentration), Wescodyne, or detergent-based disinfectant.

Waste Disposal: Dispose of viral stocks by autoclaving at 121°C for 30-45 minutes; Dispose of infected liquid cultures by decontamination with chlorine bleach (10% f.c.) for 10 minutes and then dispose of in sink or following

the local code. Dispose of infected animal carcasses or tissues by incineration

Follow all Federal, State, and Local regulations.

Special Protective Information:

Although the agent belongs to BSL-1, the personal protection equipments are recommended when handling this agent.

Special Precautions or Comments:

Retro-CAG-eGFP-RG and cultures should be handled by qualified microbiologists using appropriate safety procedures and precautions. Detailed discussions of laboratory safety procedures are provided in **Laboratory Safety: Principles and Practice** (Fleming et al., ASM Press, Washington D.C., 1995), and in the U.S. Government Publication, **Biosafety in Microbiological and Biomedical Laboratories** (CDC, 1999). This and other publications are available at the Centers for Disease Control Office of Health and Safety's website at

<http://www.cdc.gov/biosafety/publications/bmb15/BMBL.pdf>

REFERENCES

1. Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. *Pharmacol Rev.* 2000 Dec;52(4): 493-511.
2. Palu G, Parolin C, Takeuchi Y, Pizzato M. Progress with retroviral gene vectors. *Rev. Med Virol.* 2000 May-Jun;10(3): 185-202

Notes: The above information is accurate to the best of our knowledge. All materials and mixtures may present unknown hazards and should be used with caution. The user should exercise independent judgment as to the hazards based on all sources of information available. The Tribioscience Inc. shall not be held liable for any damage resulting from the handling or use of the above product.